摘要
心力衰竭是多种心脏疾病的终末阶段,其中以射血分数降低型心力衰竭患者居多。药物治疗对此类患者的疗效仍有较大局限性。而心脏移植因价格昂贵、供体有限、术后排异等问题在临床尚无法广泛展开。近年来器械治疗的发展为此类心衰患者的治疗带来转机。该文主要通过介绍2种用于治疗HFr EF患者的新型植入式装置,心脏收缩力调节器和压力反射激活疗法的原理、设计、临床试验结果和最新进展,探讨其研究方向与挑战。
Heart failure is the terminal stage of many heart diseases,most of which are patients with reduced ejection fraction.The efficacy of drug therapy for these patients is still limited.However,heart transplantation has not been widely carried out in clinic due to its high price,limited donors and postoperative rejection.In recent years,the development of instrumentation therapy has brought about a breakthrough in the treatment of such patients with heart failure.In this review,we introduce the principle,design,clinical trial results and recent progress of two new implantable devices for the treatment of HFrEF patients,cardiac contractility modulation(CCM)and baroreflex activation therapy(BAT),and discuss their research directions and challenges.
作者
凡雪静
何强
冯世华
王敬萍
FAN Xuejing;HE Qiang;FENG Shihua;WANG Jingping(Graduate School,Shanxi Medical University,Taiyuan,030000;Cardiovascular Medicine Department,Shanxi Cardiovascular Hospital,Taiyuan,030000)
出处
《中国医疗器械杂志》
2023年第2期185-189,共5页
Chinese Journal of Medical Instrumentation
关键词
射血分数降低型心力衰竭
器械治疗
新器械
新技术
heart failure with reduced ejection fraction
devices therapy
new device
new technology
